Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2007;115:949-952
doi: 10.1161/CIRCULATIONAHA.106.683110
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Morrow, D. A.
Right arrow Articles by de Lemos, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Morrow, D. A.
Right arrow Articles by de Lemos, J. A.
Right arrowPubmed/NCBI databases
*Substance via MeSH
Related Collections
Right arrow Secondary prevention
Right arrow Risk Factors
Right arrow Acute coronary syndromes
Right arrow Other diagnostic testing

(Circulation. 2007;115:949-952.)
© 2007 American Heart Association, Inc.


Editorial

Benchmarks for the Assessment of Novel Cardiovascular Biomarkers

David A. Morrow, MD, MPH; James A. de Lemos, MD

From the TIMI Study Group (D.A.M.), Cardiovascular Division, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Mass; and the Donald W. Reynolds Cardiovascular Clinical Research Center (J.A.d.L.), University of Texas Southwestern Medical Center, Dallas, Tex.

Correspondence to Dr David A. Morrow, MD, MPH, TIMI Study Group/Cardiovascular Division, Department of Medicine, Brigham & Women’s Hospital, 350 Longwood Ave, 1st Floor, Boston, MA 02115. E-mail dmorrow@partners.org


Key Words: Editorials • angina, unstable • biomarkers • diagnosis • myocardial infarction • prognosis


An extract of the first 250 words of the full text is provided, because this article has no abstract.
 


*    Introduction
 
The investigation of novel circulating serum and plasma biomarkers in patients with cardiovascular disease has been accelerating at a remarkable pace. For example, a Medline search that uses the terms "biomarkers" and "acute coronary syndromes" (ACS) reveals an approximate tripling in the number of published reports during the 2-year interval from 2003 to 2004 compared with the period from 2001 to 2002, and this number more than doubled from 2005 to 2006. Although this expanding body of research has established firm evidence for the value of biomarkers, such as for diagnosis and risk assessment among patients with suspected ACS,1 it has also deluged the clinical and research communities with candidate biomarkers, very few of which are likely to survive the test of time as useful clinical tools.2,3 It is thus increasingly important for researchers, manufacturers, regulators, and clinicians to critically appraise the value of new biomarkers as they emerge as candidates for further investigation and possible clinical application. The superb report by Wollert and colleagues4 in the present issue of Circulation on growth differentiation factor-15 (GDF-15) as a biomarker for prognostic assessment in ACS provides an opportunity to outline a basic set of benchmarks against which new markers can be evaluated.

Article p 962


*    Criteria for the Appraisal of Novel Biomarkers
 
Assessment of the clinical potential of a novel biomarker5 may be structured around 3 fundamental questions (Figure): (1) Can the clinician measure it? (2) Does it add new information? (3) Does it help the clinician to manage patients?


Figure Removed (Available Only in the Full Text)
View larger version (49K):



 
A, Criteria for assessment of novel . . . [Full Text of this Article]




This article has been cited by other articles:


Home page
CirculationHome page
T. S. Perlstein and M. A. Creager
The Ankle-Brachial Index as a Biomarker of Cardiovascular Risk: It's Not Just About the Legs
Circulation, November 24, 2009; 120(21): 2033 - 2035.
[Full Text] [PDF]


Home page
ANN INTERN MEDHome page
M. Helfand, D. I. Buckley, M. Freeman, R. Fu, K. Rogers, C. Fleming, and L. L. Humphrey
Emerging Risk Factors for Coronary Heart Disease: A Summary of Systematic Reviews Conducted for the U.S. Preventive Services Task Force
Ann Intern Med, October 6, 2009; 151(7): 496 - 507.
[Abstract] [Full Text] [PDF]


Home page
Circ Cardiovasc GenetHome page
A. Rohatgi and J. A. de Lemos
The Report Card on Growth Differentiation Factor 15: Consistent Marks But Not Yet Ready for Promotion
Circ Cardiovasc Genet, June 1, 2009; 2(3): 209 - 211.
[Full Text] [PDF]


Home page
Eur Heart JHome page
J. Kastrup, J. S. Johansen, P. Winkel, J. F. Hansen, P. Hildebrandt, G. B. Jensen, C. M. Jespersen, E. Kjoller, H. J. Kolmos, I. Lind, et al.
High serum YKL-40 concentration is associated with cardiovascular and all-cause mortality in patients with stable coronary artery disease
Eur. Heart J., May 1, 2009; 30(9): 1066 - 1072.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
K. S. Woo
Perusal of risk stratification of acute myocardial infarction for half a century
Eur. Heart J., May 1, 2009; 30(9): 1030 - 1032.
[Full Text] [PDF]


Home page
Arch Intern MedHome page
T. S. Perlstein, J. Weuve, M. A. Pfeffer, and J. A. Beckman
Red Blood Cell Distribution Width and Mortality Risk in a Community-Based Prospective Cohort
Arch Intern Med, March 23, 2009; 169(6): 588 - 594.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
A. Gonzalez, B. Lopez, S. Ravassa, J. Beaumont, T. Arias, N. Hermida, A. Zudaire, and J. Diez
Biochemical markers of myocardial remodelling in hypertensive heart disease
Cardiovasc Res, February 15, 2009; 81(3): 509 - 518.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
NACB LMPG Committee Members, G. L. Myers, R. H.M. Christenson, M. Cushman, C. M. Ballantyne, G. R. Cooper, C. M. Pfeiffer, S. M. Grundy, D. R. Labarthe, D. Levy, et al.
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Emerging Biomarkers for Primary Prevention of Cardiovascular Disease
Clin. Chem., February 1, 2009; 55(2): 378 - 384.
[Abstract] [Full Text] [PDF]


Home page
ESC Textbook of Cardiovascular MedicineHome page
C. W. Hamm, H. Möllmann, J.-P. Bassand, and F. van de Werf
CHAPTER 16 Acute Coronary Syndromes
ESC Textbook of Cardiovascular Medicine, January 1, 2009; 2(1): med-9780199566990-chapter - med-9780199566990-chapter.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
E. Braunwald
Biomarkers in Heart Failure
N. Engl. J. Med., May 15, 2008; 358(20): 2148 - 2159.
[Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
M. Lankeit, T. Kempf, C. Dellas, M. Cuny, H. Tapken, T. Peter, M. Olschewski, S. Konstantinides, and K. C. Wollert
Growth Differentiation Factor-15 for Prognostic Assessment of Patients with Acute Pulmonary Embolism
Am. J. Respir. Crit. Care Med., May 1, 2008; 177(9): 1018 - 1025.
[Abstract] [Full Text] [PDF]


Home page
J. Appl. Physiol.Home page
M. Nieuwdorp, M. C. Meuwese, H. L. Mooij, C. Ince, L. N. Broekhuizen, J. J. P. Kastelein, E. S. G. Stroes, and H. Vink
Measuring endothelial glycocalyx dimensions in humans: a potential novel tool to monitor vascular vulnerability
J Appl Physiol, March 1, 2008; 104(3): 845 - 852.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
J. A. de Lemos and M. O'Donoghue
The Skinny on Fatty Acid-Binding Protein
J. Am. Coll. Cardiol., November 20, 2007; 50(21): 2068 - 2070.
[Full Text] [PDF]


Home page
J Am Coll CardiolHome page
R. P. Giugliano and E. Braunwald
The Year in Non ST-Segment Elevation Acute Coronary Syndrome
J. Am. Coll. Cardiol., October 2, 2007; 50(14): 1386 - 1395.
[Full Text] [PDF]